Kushenol K

Kushenol K

SCHEMBL564142

C=C(C)C(CCC(C)(C)O)Cc1c(O)cc(OC)c2c1O[C@H](c1ccc(O)cc1O)[C@H](O)C2=O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BACE1 P56817 9/20 0.72
▸ SLC5A1 P13866 2/20 0.56
▸ SLC5A2 P31639 2/20 0.56
▸ PTGS1 P23219 2/20 0.56
▸ ESR1 P03372 2/20 0.56
▸ SOAT1 P35610 1/20 0.56
▸ BCHE P06276 1/20 0.56
▸ ACHE P22303 1/20 0.56
▸ CACNA1G O43497 1/20 0.46
▸ CACNA1H O95180 1/20 0.46
▸ ABCG2 Q9UNQ0 1/20 0.46
▸ PDPK1 O15530 1/20 0.37
▸ PRKCA P17252 1/20 0.37
▸ PRKCQ Q04759 1/20 0.37
▸ AKR1B10 O60218 1/20 0.37
▸ AKR1B1 P15121 1/20 0.37
▸ SLCO2B1 O94956 1/20 0.35
▸ SLCO1B3 Q9NPD5 1/20 0.35
▸ SLCO1B1 Q9Y6L6 1/20 0.35
▸ ELANE P08246 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Kushenol K SCHEMBL27013479 1.00 BACE1 (0.72) BACE1SLC5A1SLC5A2PTGS1ESR1
Kushenol N SCHEMBL564366 0.87 BACE1 (0.73) BACE1SLC5A1SLC5A2PTGS1ESR1
Kushenol N SCHEMBL564568 0.87 BACE1 (0.73) BACE1SLC5A1SLC5A2PTGS1ESR1
Kushenol N SCHEMBL27013512 0.87 BACE1 (0.73) BACE1SLC5A1SLC5A2PTGS1ESR1
Kushenol N SCHEMBL30451391 0.87 BACE1 (0.73) BACE1SLC5A1SLC5A2PTGS1ESR1
Kushenol N SCHEMBL27013513 0.87 BACE1 (0.73) BACE1SLC5A1SLC5A2PTGS1ESR1
Kurarinol SCHEMBL27013517 0.84 BACE1 (1.00) BACE1SLC5A1SLC5A2PTGS1ESR1
Kurarinol SCHEMBL29460259 0.84 BACE1 (1.00) BACE1SLC5A1SLC5A2PTGS1ESR1
SCHEMBL29931025 0.81 BACE1 (0.91) BACE1SLC5A1SLC5A2PTGS1ESR1
Kushenol X SCHEMBL4809925 0.77 BACE1 (0.72) BACE1SLC5A1SLC5A2PTGS1ESR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023219526-A1 MULTITARGET ANTIVIRAL DIETARY SUPPLEMENT PROKIN MILAN (RS) 2023-11-16 — — WO claimed
CN-1348762-A Application of kusheng (sophora Flavescences) flavone in preparing hypoglycemic LUZHOU BAOGUANG PHARMACEUTICAL (CN) 2002-05-15 — — CN claimed
CN-118593473-A Application of kurarinol A in preparation of IDO1 inhibitor acting on non-small cell lung cancer cells, pharmaceutical composition, application and method for improving lung cancer cell radiotherapy sensitivity 厦门承葛生物科技有限公司 2024-09-06 — — CN disclosed
US-20240016777-A1 COMPOUNDS AND METHODS FOR TREATING VIRAL INFECTIONS BETH ISRAEL DEACONESS MEDICAL CENTER, INC. 2024-01-18 — — US disclosed
WO-2023219526-A1 MULTITARGET ANTIVIRAL DIETARY SUPPLEMENT PROKIN MILAN (RS) 2023-11-16 — — WO disclosed
US-10744219-B2 Air freshener composition and preparation method thereof Guorun Biotechnology (Shenzhen) Co., Ltd. (CN) 2020-08-18 — — US disclosed
US-20200164096-A1 AIR FRESHENER COMPOSITION AND PREPARATION METHOD THEREOF Guorun Biotechnology (Shenzhen) Co., Ltd. (CN) 2020-05-28 — — US disclosed
EP-3388137-B1 AIR FRESHENER COMPOSITION AND PREPARATION METHOD THEREFOR WANG JINGNING (CN) 2020-04-15 — — EP disclosed
EP-3388137-A1 AIR FRESHENER COMPOSITION AND PREPARATION METHOD THEREFOR Wang, Jingning (CN) 2018-10-17 — — EP disclosed
CN-102908341-A Vitexicarpin used as pharmaceutical active ingredient with anti-angiogenesis function UNIV TSINGHUA 2013-02-06 — — CN disclosed
CN-102030812-B Timosaponin A-III serving as medicinal active ingredient with angiogenesis resistance UNIV TSINGHUA 2012-07-04 — — CN disclosed
WO-2010066150-A9 GENE NETWORK-BASED METHOD FOR CONFIRMING DRUG ACTION 清华大学 (CN) 2011-07-21 — — WO disclosed
CN-102030812-A Timosaponin A-III serving as medicinal active ingredient with angiogenesis resistance UNIV TSINGHUA 2011-04-27 — — CN disclosed
CN-102028679-A Vitexin as active ingredient of medicine with anti-angiogenesis effect UNIV TSINGHUA 2011-04-27 — — CN disclosed
JP-2008222622-A Na+/GLUCOSE TRANSPORTER INHIBITOR NIPPON SUISAN KAISHA LTD 2008-09-25 — — JP disclosed
WO-2007126259-A1 COMPOSITIONS FOR TREATING AUTOIMMUNE DISEASE CONTAINING EXTRACTS OF SOPHORA FLAVESCENS PURIMED CO., LTD. (KR) 2007-11-08 — — WO disclosed
WO-2006057893-A2 COMPOSITION, DELIVERY SYSTEM AND METHOD FOR PROMOTING HEALTHY SEXUAL FUNCTION MCCLEARY EDWARD LARRY (US) 2006-06-01 — — WO disclosed
US-20060110477-A1 Composition and method for supporting and promoting healthy sexual function and prevention and treatment of sexual dysfunction MCCLEARY EDWARD L 2006-05-25 — — US disclosed
US-20060110478-A1 Delivery system and method for supporting and promoting healthy sexual function and prevention and treatment of sexual dysfunction MCCLEARY EDWARD L 2006-05-25 — — US disclosed
CN-1348762-A Application of kusheng (sophora Flavescences) flavone in preparing hypoglycemic LUZHOU BAOGUANG PHARMACEUTICAL (CN) 2002-05-15 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060110478-A1 Delivery system and method for supporting and promoting healthy sexual function and prevention and treatment of sexual dysfunction PDE5A, PDE2A, SLC25A20 BACE1 3695/4885SLC5A1 1193/4885SLC5A2 1702/4885
US-20060110477-A1 Composition and method for supporting and promoting healthy sexual function and prevention and treatment of sexual dysfunction SHBG, KYNU, SLC25A20 BACE1 2579/4885SLC5A1 2518/4885SLC5A2 3313/4885
US-20240016777-A1 COMPOUNDS AND METHODS FOR TREATING VIRAL INFECTIONS THPO, SERPINB1, SERPINC1 BACE1 3298/4885SLC5A1 77/4885SLC5A2 256/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback